Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

4.0 weeks (range 9-112 weeks) in the placebo arm(1).

In the study, the definition of angiomyolipoma response included a reduction of at least 50% relative to baseline in the sum of the volumes of all target lesions, and the absence of new lesions greater than or equal to one centimeter in diameter, with a confirmed response by radiographic scan approximately 12 weeks later(1).

Everolimus demonstrated superiority to placebo for both secondary endpoints assessed: skin lesion response rate and time to angiomyolipoma progression per central review. Skin lesion response rate, defined as the proportion of patients with a best overall skin lesion response of either complete clinical response or partial response, was 26% in patients (20 of 77) on everolimus and 0% (0 of 37) on placebo (p=0.0002). Median time to angiomyolipoma progression (time from date of randomization to date of first documented angiomyolipoma progression) was 11.37 months in the placebo arm and was not reached in the everolimus arm. Progressions were observed in 4% of patients (3 of 79) on everolimus and 21% (8 of 39) on placebo. The estimated progression-free rates at six months were 98% on everolimus and 83% on placebo (p<0.0001)(1).

The most common adverse events (AEs) in the everolimus arm (with an incidence of at least 20%) included stomatitis, nasopharyngitis, acne, headache, cough and hypercholesterolaemia. Renal events were less frequent in the everolimus arm compared to the placebo arm. The most common Grade 3 AEs in the everolimus arm (with an incidence of at least 2%) were amenorrhea, aphthous stomatitis, decreased blood phosphorus and mouth ulceration. Single Grade 4 cases of convulsion, increased blood uric acid, hypertensive crisis and neutropenia were reported in the everolimus arm(1).

Adverse events observed in this study were consistent with the known safety profile of everolimus in the TSC setting. Adverse events leading to trial discontinuation were rep
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada ... its Board of Directors, enhancing executive oversight and ... a leading licensed producer of medicinal cannabis in ... 13 years, experience in producing and supplying government-regulated ... Canada. As previously announced in ...
(Date:8/21/2014)... (NASDAQ: CYBX ) today announced results for the ... 1   Operating results for the first quarter ... 2014, and other achievements, include: , Worldwide net product ... Strong international net sales of $13.2 million, an increase of ... product sales reached a new high of $58.8 million, an ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
... SANTA MARIA, Calif., Feb. 14, 2011 Hardy Diagnostics, ... the release of HardyCHROM™ SS, a highly selective chromogenic ... for the isolation and differentiation of Salmonella ... two pathogens can be easily distinguished from non-pathogenic enteric ...
... MedQuist Holdings Inc. (Nasdaq: MEDH ), formerly ... documentation solutions for the U.S. healthcare system, today announced ... shares of its common stock.  The shares began trading ... under the ticker symbol MEDH. In ...
Cached Medicine Technology:The Only Chromogenic Medium That Detects Both Salmonella and Shigella! 2MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 2MedQuist Holdings Inc. Announces Closing of Its Initial U.S. Public Offering and Acquisition of Additional Shares of MedQuist Inc. 3
(Date:8/21/2014)... California (PRWEB) August 21, 2014 The ... initial plans for entertainment and programming for its inaugural ... On Sunday, October 12, 2014, from 11 a.m. to ... closed to all cars and the downtown will be ... activities, curated by Community Arts Resources (CARS), for all ...
(Date:8/21/2014)... -- Among seniors, dimming vision may be tied to ... than 2,500 people, aged 65 to 84, who were assessed ... and eight years later. Vision loss over time was ... during the study period, the researchers reported. Although the ... Christ of Purdue University in West Lafayette, Ind., offered up ...
(Date:8/21/2014)... A new study published this week ... disability associated with speech problems from 2001-02 to 2010-11 ... increase in disability associated with hearing problems. The data ... of children who are experiencing communication disorders, according to ... On a broader level, the new study, Changing ...
(Date:8/21/2014)... Aug. 21, 2014 Researchers in the United Kingdom ... can quickly and accurately diagnose a number of rare ... study published online today in Ophthalmology , ... Using a single test, doctors were able to tailor ... mutations reducing the time and money spent on diagnosis ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... Market by Pollutant Control System (FGD, DeNOx, Particulate ... Iron & Steel, Chemical & Others) - Global ... the global industrial flue gas treatment systems & ... global market size in terms of value. The ...
Breaking Medicine News(10 mins):Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... have found that recognisation of West Nile Virus (WNV) ... allows the virus to cross the blood-brain barrier (BBB) ... stranded RNA (ssRNA) flavivirus with a life cycle that ... can become infected. In humans, infection is generally asymptomatic ...
... a conference of the International Aids Society Conference in// ... men were 65 per cent less likely to become ... studies have suggested that circumcision lowers rate of HIV ... Africa, where some tribes routinely circumcised while others did ...
... Hail protein! So finally scientists have been able to zero ... The basis of the well known “rage” diets like Atkins ... restriction of carbohydrate foods. As a consequence protein in the ... for weight loss and rightly so. These diets work in ...
... may be using baby talks for longer times than ... warns scientists. ,Linda Crowe, associate professor in the ... said that it’s important for the parents to identify ... delays can range from a child being slow to ...
... and other clinically important conditions that would be missed ... according to a study in the August issue of Radiology. ... may be as significant as the chance of finding cancer ... at the Veterans Affairs Medical Center and associate professor and ...
... to conventional// therapy may soon get help from a ... a professor of gastroenterology at the University of Alberta, ... and the University of North Carolina administered probiotic bacteria ... aged 18-65. ,Probiotics are preparations of living ...
Cached Medicine News:Health News:Toll-like Receptor (Tlr3) Attachment Leads To Lethal Encephalitis 2Health News:More News That Circumcision Could Reduce risk of HIV infection 2Health News:Weighty problem: Protein is the solution? 2Health News:Weighty problem: Protein is the solution? 3Health News:Weighty problem: Protein is the solution? 4Health News:Language Delays May Not Be Normal In Children 2Health News:Virtual Colonoscopy May Be Better Than Real-time Colonoscopy 2
Nidek offers 3-Dx Digital stereo camera to provide a complete and comprehensive digital imaging platform....
Measurement of progressive multi-focal lenses is fast and easy with the CLM-3000 auto-lensmeter. The data is represented in a simple to understand bar graphic display....
Auto Lensmeter LM-970...
Autolensmeter with black/white monitor and no internal printer....
Medicine Products: